Biogen Inc.
0 products tracked · names used in filings: Biogen Inc.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
LEQEMBI IQLIK: PDUFA target action date (subcutaneous treatment initiation)
Biogen Inc. (BIIB); status: set; "…LEQEMBI IQLIK subcutaneous treatment initiation granted FDA Priority Review with a PDUFA date of May 24, 2026; regulatory filings under review in Japan and China • FDA Breakthrough Therapy Designation granted for litifilimab in c"; filed 2026-02-06 · source
SPINRAZA: PDUFA target action date (high dose regimen)
Biogen Inc. (BIIB); status: set; "FDA PDUFA of April 3, 2026 • BTK degrader (BIIB145) targeting autoimmune diseases Phase 1 study initiated in healthy volunteers Full year 2026 fin"; filed 2026-02-06 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.